Mild to Moderate Psoriasis
7
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
1 terminated out of 7 trials
80.0%
-6.5% vs benchmark
29%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
A Phase III Study in Subjects With Mild to Moderate Psoriasis.
Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis
Topical Application of AS101 for the Treatment of Psoriasis
Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)
Determination of the Efficacy and Safety of Psirelax in the Relief of the Disease in Psoriasis